Product Name:
MARK3-pT507
Product Number:
ab-pk697
Target Full Name: MAP/microtubule affinity-regulating protein-serine kinase 3
Target Alias: Cdc25C- associated protein kinase 1; Cdc25C-associated protein kinase 1; CTAK1; C-TAK1; ELKL motif kinase 2; KP78; PAR1A; Protein kinase STK10; Ser/Thr protein kinase PAR-1; Serine/threonine protein kinase p78; Serine/threonine-protein kinase p78
Product Type Specific: MARK3 protein kinase phosphosite-specific antibody
Antibody Code: PK697
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T507
Protein UniProt: P27448
Protein SigNET: MARK3
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MARK3 sequence peptide Cat. No.: PE-04ANR99
Antibody Immunogen Sequence: RRN(pT)YVC(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R504 to C510; in the C-terminal quarter of the protein kinase. The effect of T530 phosphorylation is unclear. This is the major in vivo phosphorylation site in MARK3 (≥317 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). MARK3 is known to be phosphorylated at this site in vitro by PKACa (PRKACA).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Rat | Mouse | Platypus | Frog.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 80-85 kDa.
Related Product 1: MARK3 (504-510) pT507 antibody blocking peptide (Cat. No.: PE-04ANR99)
Related Product 2: MARK1-ANT pan-specific antibody (Cat. No.: AB-NK098-2)
Related Product 3: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK694)
Related Product 4: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK695)
Related Product 5: MARK2-ANT pan-specific antibody (Cat. No.: AB-NK275-1)
Related Product 6: MARK2-BCT pan-specific antibody (Cat. No.: AB-NK275-2)
Related Product 7: MARK3-ANT pan-specific antibody (Cat. No.: AB-NK276-1)
Related Product 8: MARK3-BCT pan-specific antibody (Cat. No.: AB-NK276-2)
Related Product 9: MARK4-ANT pan-specific antibody (Cat. No.: AB-NK277-1)
Related Product 10: MARK4-NT pan-specific antibody (Cat. No.: AB-NK277-2)
Scientific Background: MARK3 (Microtubule Affinity Regulating Kinase 3; C-TAK1) is a ~110 kDa protein-serine/threonine kinase of the CAMK group and CAMKL family, and regulates cell polarity, microtubule stability, and cell cycle progression. It phosphorylates microtubule-associated proteins (MAP2, MAP4, TAU), reducing their affinity for microtubules, and acts as a key mediator in the Hippo signaling pathway by inhibiting LATS1. It features an N-terminal kinase domain, a UBA (ubiquitin-associated) domain, and a C-terminal spacer. Its activity is controlled by phosphorylation from upstream kinases like LKB1 (serine/threonine-protein kinase STK11) and interaction with 14-3-3 scaffolding proteins. Phosphorylation of Thr-234 and Ser-238 in MARK3 increases phosphotransferase activity. T211A substitution is involved in decreased phosphorylation and activation by LKB1/LKB1 complex. Phosphorylation of Thr-95 and Ser-96 inhibits phosphotransferase activity. MARK3 phosphorylates CDC25C on Ser-216, controlling the G2/M transition of the cell cycle. It also plays a role in regulating the localization of histone deacetylases (HDAC7) and MITF. MARK3 regulates bone mineral density. It is also associated with carcinogenesis, particularly in the pancreas, and has been identified in a form of genetic recessive blindness. This description may include information annotated by UniProt and/or Google AI.